The Food and Drug Administration (FDA) first approved the usage of prostate-specific antigen (PSA) in PCa in 1986, and this revolutionized the diagnosis process of PCa, and allowed the detection in earlier stages, in contrast to previously used techniques where most of the cases were diagnosed in locally advanced or metastases stages. This evidence concerns the gene KLK3 and posterior cortical atrophy.